Journal: Cell Proliferation

Article Title: Glycomics reveal that ST6GAL1‐mediated sialylation regulates uterine lumen closure during implantation

doi: 10.1111/cpr.13169

Figure Lengend Snippet: Expression patterns of the sialylated glycans as well as the mRNA and protein expression of ST6GAL1 and ST6GAL2 in pig endometrium during implantation. (A) The 19 possible α2,3/6‐sialylated N‐glycans identified by MALDI‐TOF MS. Fucose ; N‐acetylglucosamine ; N‐acetyl neuraminic acid ; N‐glycolyl neuraminic acid ; mannose ; Galactose . (B) Representative images of lectin fluorescence assays taken from pig endometrium on gestational days 12, 15 and 18 (n = 3 gilts/gestational day). MAL‐II was used to detect α2,3‐linked sialic acid residues. SNA was used to detect α2,6‐linked sialic acid residues. (C) Expression levels of ST6GAL1 and ST6GAL2 in pig endometrium on gestational days 12, 15 and 18 measured by qRT‐PCR (n = 3 gilts/gestational day). The error bars represent the standard error. Mean is denoted by a red line. Nonparametric Mann‐Whitney one tail test was used for statistical analysis. (D) Distributions of ST6GAL1 and ST6GAL2 in pig endometrium on gestational days 12, 15 and 18 (n = 3 gilts/gestational day). The positive signal is in green, while the nucleus is in blue. NC, negative control. LE, endometrial luminal epithelium. GD, gestational day. Scale bar = 50 µm

Article Snippet: The primary antibodies used were ST6GAL1 (1:50, ab77676, abcam), ST6GAL2 (1:50, AF7747; R&D Systems), E‐cadherin (1:50, ab40772; abcam), β‐catenin (1:50, ab6302; abcam), Vimentin (1:50; sc‐73258), Rac1 (1:30, 66122–1‐Ig; Proteintech) and RhoA (1:50, 10749–1‐Ig; Proteintech).

Techniques: Expressing, Fluorescence, Quantitative RT-PCR, MANN-WHITNEY, Negative Control

Journal: iScience

Article Title: Niche-expressed Galectin-1 is involved in pre-B acute lymphoblastic leukemia relapse through pre-B cell receptor activation

doi: 10.1016/j.isci.2023.106385

Figure Lengend Snippet: GAL1+ mesenchymal stromal cells favor the development of murine Pre-BCR+ B-ALL

Article Snippet: Pre-B ALL from patient #IPC6 and Nalm6 were incubated 30 min at 4 °C in PBS with 70 nM recombinant human GAL1 (kind gift from Dr. L. Elantak) in absence or in presence of different concentrations of thiodigalactoside or of the GAL1 inhibitor OTX008 (MedChemExpress).

Techniques:

Journal: iScience

Article Title: Niche-expressed Galectin-1 is involved in pre-B acute lymphoblastic leukemia relapse through pre-B cell receptor activation

doi: 10.1016/j.isci.2023.106385

Figure Lengend Snippet: Pre-BCR signaling and human pre-B ALL growth are impaired in the absence of GAL1

Article Snippet: Pre-B ALL from patient #IPC6 and Nalm6 were incubated 30 min at 4 °C in PBS with 70 nM recombinant human GAL1 (kind gift from Dr. L. Elantak) in absence or in presence of different concentrations of thiodigalactoside or of the GAL1 inhibitor OTX008 (MedChemExpress).

Techniques:

Journal: Cancers

Article Title: Autocrine Signaling of NRP1 Ligand Galectin-1 Elicits Resistance to BRAF-Targeted Therapy in Melanoma Cells

doi: 10.3390/cancers12082218

Figure Lengend Snippet: Galectin-1 upregulation in melanoma samples and cell lines resistant to BRAF-targeted therapy. ( A ) The graph shows Galectin-1 (LGALS1 gene) mRNA expression variation in paired melanoma samples (obtained from seven patients, indicated by black diamonds) before treatment with BRAF inhibitors and after the onset of secondary resistance (Log2 ratio resistant/pretherapy), as well as in A375 and SK-MEL-28 melanoma cells before and after developing resistance to 2μM PLX-4720 (Log2 ratio Resistant/Parental; n = 3). ( B ) Analysis of Galectin-1 protein levels (by PikoKine ELISA assay) in conditioned media (CM) derived from either parental or PLX4720-resistant A375 and SK-MEL-28 (PLX-resistant) cells. Data are normalized to levels detected in the respective parental cells and represent the average of a technical duplicate. Statistical significance was assessed by t -test, comparing parental and their derived PLX-resistant cell lines; *** p < 0.0001.

Article Snippet: Galectin-1 concentrations in CM were measured by PikoKine ELISA assay (category EK0762; Boster Biological Technology, Pleasanton, CA, USA), according to the manufacturer’s protocol.

Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Derivative Assay

Journal: Molecular carcinogenesis

Article Title: CD137 Protein Expression Pattern Determines the Functional Role of Galectin-9 in Colorectal Cancer.

doi: 10.1002/mc.23838

Figure Lengend Snippet: FIGURE 6 | Effects of exogenous Galectin‐9 intervention and/or CD137 overexpression on the CT26 tumor model. (A) Collective photograph of the mice at the end of the experiment. (B) Collective photograph of the completely excised tumor tissues from each group of mice. (C) Growth curves of tumors in each group of mice. (D) Trends in body weight changes for each group of mice. (E) Representative images of the distribution of Ki67 immunohistochemical staining in the tumor tissues of each group. (F) Comparative analysis of the proportion of Ki67 positive cells in the tumor tissues of each group. Data are presented as mean ± SD (n = 6). *p < 0.05 versus vehicle or Gal‐9, #p < 0.05 versus CD137‐OE. SD, standard deviation.

Article Snippet: The mice were divided into the following experimental groups: Gal‐9 Group: Mice were given a daily intravenous injection of 30 μg/mouse of Gal‐9 (MedChemExpress, Monmouth Junction, NJ, USA) [22] after tumor cell inoculation.

Techniques: Over Expression, Immunohistochemical staining, Staining, Standard Deviation

Journal: Molecular carcinogenesis

Article Title: CD137 Protein Expression Pattern Determines the Functional Role of Galectin-9 in Colorectal Cancer.

doi: 10.1002/mc.23838

Figure Lengend Snippet: FIGURE 7 | Effects of Galectin‐9 supplementation and CD137 knockout/overexpression on the MC38 tumor model. (A) Collective photograph of the mice at the end of the experiment. (B) Collective photograph of the completely excised tumor tissues from each group of mice. (C) Growth curves of tumors in each group of mice. (D) Trends in body weight changes for each group of mice. (E) Representative images of the distribution of Ki67 immunohistochemical staining in the tumor tissues of each group. (F) Comparative analysis of the proportion of Ki67 positive cells in the tumor tissues of each group. Data are presented as mean ± SD (n = 6). *p < 0.05 versus vehicle, #p < 0.05 versus Gal‐9, &p < 0.05 versus CD137‐OE, ▲p < 0.05 versus Tnfrsf9‐KO. SD, standard deviation.

Article Snippet: The mice were divided into the following experimental groups: Gal‐9 Group: Mice were given a daily intravenous injection of 30 μg/mouse of Gal‐9 (MedChemExpress, Monmouth Junction, NJ, USA) [22] after tumor cell inoculation.

Techniques: Knock-Out, Over Expression, Immunohistochemical staining, Staining, Standard Deviation

Journal: Molecular carcinogenesis

Article Title: CD137 Protein Expression Pattern Determines the Functional Role of Galectin-9 in Colorectal Cancer.

doi: 10.1002/mc.23838

Figure Lengend Snippet: FIGURE 8 | Investigating the impacts of Galectin‐9 supplementation and CD137 knockout/overexpression on the infiltration of immune cells on the tumor microenvironment of murine colon cancer. (A) Representative images of CD137 expression distribution in CT26 and MC38 colon cancer tumor tissues, demonstrated through immunohistochemical staining. (B) Comparative analysis of the proportion of CD137‐positive cells in CT26 and MC38 colon cancer tumor tissues. (C) Distribution of activated T cells in CT26 colon cancer tumor tissues, shown using CD3 and CD137 dual immunofluorescence labeling. (D, E) Comparative analysis of the proportion of CD3+ cells and CD3+CD137+ positive cells in CT26 colon cancer tumor tissues. (F) Similarly, using CD3 and CD137 dual immunofluorescence labeling, the distribution of activated T cells in MC38 colon cancer tumor tissues are shown. (G, H) Comparative analysis of the proportion of CD3+ and CD3+CD137+ positive cells in MC38 colon cancer tumor tissues. Data are presented as mean ± SD (n = 6). *p < 0.05 versus vehicle, #p < 0.05 versus Gal‐9, &p < 0.05 versus CD137‐OE, ▲p < 0.05 versus Tnfrsf9‐KO. SD, standard deviation.

Article Snippet: The mice were divided into the following experimental groups: Gal‐9 Group: Mice were given a daily intravenous injection of 30 μg/mouse of Gal‐9 (MedChemExpress, Monmouth Junction, NJ, USA) [22] after tumor cell inoculation.

Techniques: Knock-Out, Over Expression, Expressing, Immunohistochemical staining, Staining, Immunofluorescence, Labeling, Standard Deviation

Journal: Molecular carcinogenesis

Article Title: CD137 Protein Expression Pattern Determines the Functional Role of Galectin-9 in Colorectal Cancer.

doi: 10.1002/mc.23838

Figure Lengend Snippet: FIGURE 9 | Effects of Galectin‐9 supplementation and CD137 knockout/overexpression on T cell activation in murine colon cancer tumor tissues. (A) Representative bands of phosphorylated CD3ζ, total CD3ζ, phosphorylated ZAP70, and total ZAP70 protein expression in CT26 tumor tissues were detected using western blot analysis. (B) Quantitative analysis compared the levels of phosphorylated CD3ζ in various groups of CT26 tumor tissues. (C) Quantitative analysis compared the levels of phosphorylated ZAP70 in various groups of CT26 tumor tissues. (D) Representative bands of phosphorylated CD3ζ, total CD3ζ, phosphorylated ZAP70, and total ZAP70 protein expression in MC38 tumor tissues were detected using western blot analysis. (E) Quantitative analysis compared the levels of phosphorylated CD3ζ in various groups of MC38 tumor tissues. (F) Quan- titative analysis compared the levels of phosphorylated ZAP70 in various groups of MC38 tumor tissues. Data are presented as mean ± SD (n = 6). *p < 0.05 versus vehicle, #p < 0.05 versus Gal‐9, &p < 0.05 versus CD137‐OE, ▲p < 0.05 versus Tnfrsf9‐KO. SD, standard deviation.

Article Snippet: The mice were divided into the following experimental groups: Gal‐9 Group: Mice were given a daily intravenous injection of 30 μg/mouse of Gal‐9 (MedChemExpress, Monmouth Junction, NJ, USA) [22] after tumor cell inoculation.

Techniques: Knock-Out, Over Expression, Activation Assay, Expressing, Western Blot, Standard Deviation